Inclusion Criteria:

        Initial Screening

          -  Radiologically confirmed DIPG or other diffuse intrinsic brain stem glioma (Grade III
             or IV).

          -  Patient and/or parents/guardian willing to consent to biopsy for obtaining tumor
             material for confirmatory diagnosis and/or tumor RNA extraction and amplification.

          -  Biopsy confirmation of any grade of glioma (for patients with classic DIPG on
             neuroimaging or at least grade III glioma in case of other diffuse intrinsic brain
             stem gliomas)

          -  Karnofsky Performance Status (KPS) of > 50% (KPS for > 16 years of age) or Lansky
             performance Score (LPS) of ≥ 50 (LPS for ≤ 16 years of age) assessed within 2 weeks
             prior to registration;

          -  Bone Marrow;

          -  ANC (absolute neutrophil count) ≥ 1000/µl (unsupported)

          -  Platelets ≥ 100,000/µl (unsupported)

          -  Hemoglobin > 8 g/dL (can be transfused)

          -  Renal;

          -  Serum creatinine ≤ upper limit of institutional normal

          -  Hepatic;

          -  Bilirubin ≤ 1.5 times upper limit of institutional normal for age

          -  SGPT (ALT) ≤ 3 times upper limit of institutional normal for age

          -  SGOT (AST) ≤ 3 times upper limit of institutional normal for age

          -  Patients of childbearing or child-fathering potential must be willing to use medically
             acceptable forms of birth control while being treated on this study.

          -  Signed informed consent according to institutional guidelines.

        Post Biopsy

          -  Patients with post-surgical neurological deficits should have deficits that are stable
             for a minimum of 1 week prior to registration;

          -  Pathologic diagnosis of glioma on tumor biopsy.

        Exclusion Criteria:

          -  Patients with severe dysphagia, obtundation, or tetraplegia (poor risks for anesthesia
             and biopsy procedure);

          -  Absence of tumor on biopsy specimen;

          -  Pregnant or need to breast feed during the study period (Negative serum pregnancy test
             required)

          -  Known autoimmune or immunosuppressive disease or human immunodeficiency virus
             infection;

          -  Patients with significant renal, cardiac, pulmonary, hepatic or other organ
             dysfunction;

          -  Severe or unstable concurrent medical conditions;

          -  Patients who require corticosteroids above physiologic doses (>4 mg/day dexamethasone)
             after chemoradiotherapy;

          -  Patients scheduled to receive any other concurrent anticancer or investigational drug
             therapy;

          -  Prior allergic reaction to TMZ, GM-CSF, or Td;

          -  Patients who are unwilling or unable to receive treatment and undergo follow-up
             evaluations at University of Florida;

          -  Patient and/or parent/guardian demonstrating an inability to comply with the study
             and/or follow-up procedures.